Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 3 4Phase 2 3

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NETWORK 4INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × luprolide acetate gel depot × Clear all
NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT00378690 2014-06-04

ICELAND

Astellas Pharma Inc

Phase 3 Completed
706 enrolled
Genitourinary

Prostatic Neoplasms

NCT00514917 2013-11-04

Rising PSA

Sanofi

Phase 3 Terminated
413 enrolled 21 charts
Genitourinary

Prostatic Neoplasms

NCT00283062 2012-01-26

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Sanofi

Phase 3 Completed
228 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡